GLP-1 medications: Use and Intention in a Representative Survey of Finns

Background and objectives: Semaglutide was approved for obesity treatment in 2021 in the US and 2022 in Europe, sparking global interest. Despite widespread attention, survey-based data on who uses or considers these medications—especially across socioeconomic groups, BMI categories, and experiences with weight management—remain limited. Subjects/methods: A nationally representative online survey of Finnish adults (n = 1 729) was conducted in June 2025 via a market research company using quota sampling. Use and awareness of GLP-1 medications for obesity were measured with a single item that listed widely known brands— Ozempic, Wegovy, Zepbound, and Mounjaro —to aid recognition. In regression analyses, current, past, and potential users (n = 322) are grouped together. Results 3.5% reported current and 2.0% past use of GLP-1 medications. 13.5% expressed interest in future use. Notably, ~ 40% of individuals with obesity were not interested. Bivariate analysis showed that current use was more common among women, those aged 50–69, those with household income exceeding €70,000, individuals with higher BMI, frequent weight loss attempts, experiences of weight-based discrimination, and self-blame. Regression analysis confirmed these patterns, with strongest associations for BMI ≥ 30.0, repeated or persistent weight loss attempts, experiences of discriminatory treatment due to weight, self-blaming thoughts and hopeful perceptions of GLP-1 medications. Concern about serious health risks was associated with lower likelihood of use or intention. Conclusions In clinical practice, GLP-1 users and potential users should not be viewed solely through a lens of obesity. Their long histories of weight management and experiences of obesity stigma highlight the need for sensitive, and informed communication and care.